CD137 is highly restricted to recently activated cytotoxic T cells, and CD137 + T cells at the tumor site express tumor neoantigen-reactive TCRs and are coexpressed with exhaustion markers [41–47]. Here, TNFRSF9 is linked to neoplasm.